{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:56:09Z","timestamp":1793213769523,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are recommended as first-line drugs for hypertension with diabetic nephropathy owing to their renoprotective effect; however, their effect beyond lowering blood pressure (BP) has not been confirmed. Recent studies have shown that aldosterone plays a key role in causing renal injury; therefore, it is likely that mineralocorticoid receptor (MR) blockers inhibit aldosterone-induced renal damage in different ways from ACE inhibitors and ARBs. Therefore, we investigated the mechanism of the effect of an MR blocker on reducing the urinary albumin-to-creatinine ratio (UACR) using data from a randomized, double-blind, placebo-controlled phase 3 study (ESAX-DN) of a new nonsteroidal MR blocker, esaxerenone. This <jats:italic>post hoc<\/jats:italic> analysis used a novel statistical method to quantitatively estimate the effect of esaxerenone on UACR reduction mediated, or not mediated, by changes in systolic BP (SBP) and\/or estimated glomerular filtration rate (eGFR). The proportion of the mediated effect by SBP changes to the total effect on UACR reduction was 9.8\u201310.7%; the UACR was reduced to 0.903\u20130.911 times the baseline at the end of treatment through the SBP-related pathway and to 0.422\u20130.426 times the baseline through the non-SBP-related pathway. Even considering both SBP and eGFR simultaneously, the proportion of the mediated effect was 21.9\u201328.1%. These results confirm that esaxerenone has a direct UACR-lowering effect independent of BP lowering and that its magnitude is much larger than that of the BP-dependent effect. Thus, esaxerenone could be a UACR-reducing treatment option for patients with diabetic nephropathy.<\/jats:p>","DOI":"10.1038\/s41440-022-01008-w","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T09:07:40Z","timestamp":1663060060000},"page":"437-444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial"],"prefix":"10.1038","volume":"46","author":[{"given":"Yasuyuki","family":"Okuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadayoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Shikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Sawanobori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"1008_CR1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"1008_CR2","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","volume":"366","author":"JP Casas","year":"2005","unstructured":"Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026\u201333.","journal-title":"Lancet"},{"key":"1008_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/ajh.2011.180","volume":"25","author":"V Daien","year":"2012","unstructured":"Daien V, Duny Y, Ribstein J, du Cailar G, Mimran A, Villain M, et al. Treatment of hypertension with renin-angiotensin system inhibitors and renal dysfunction: a systematic review and meta-analysis. Am J Hypertens. 2012;25:126\u201332.","journal-title":"Am J Hypertens"},{"key":"1008_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","volume":"116","author":"L Te Riet","year":"2015","unstructured":"Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116:960\u201375.","journal-title":"Circ Res"},{"key":"1008_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.pcad.2016.10.002","volume":"59","author":"C Bavishi","year":"2016","unstructured":"Bavishi C, Bangalore S, Messerli FH. Renin angiotensin aldosterone system inhibitors in hypertension: is there evidence for benefit independent of blood pressure reduction? Prog Cardiovasc Dis. 2016;59:253\u201361.","journal-title":"Prog Cardiovasc Dis"},{"key":"1008_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/jvp.12848","volume":"43","author":"S Spencer","year":"2020","unstructured":"Spencer S, Wheeler-Jones C, Elliott J. Aldosterone and the mineralocorticoid receptor in renal injury: a potential therapeutic target in feline chronic kidney disease. J Vet Pharm Ther. 2020;43:243\u201367.","journal-title":"J Vet Pharm Ther"},{"key":"1008_CR7","doi-asserted-by":"publisher","first-page":"204800401452244","DOI":"10.1177\/2048004014522440.","volume":"3","author":"M Hargovan","year":"2014","unstructured":"Hargovan M, Ferro A. Aldosterone synthase inhibitors in hypertension: current status and future possibilities. JRSM Cardiovasc Dis. 2014;3:2048004014522440. https:\/\/doi.org\/10.1177\/2048004014522440.","journal-title":"JRSM Cardiovasc Dis"},{"key":"1008_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","volume":"79","author":"S Duggan","year":"2019","unstructured":"Duggan S. Esaxerenone: First Global Approval. Drugs. 2019;79:477\u201381.","journal-title":"Drugs"},{"key":"1008_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41440-018-0187-1","volume":"42","author":"L Li","year":"2019","unstructured":"Li L, Guan Y, Kobori H, Morishita A, Kobara H, Masaki T, et al. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats. Hypertens Res. 2019;42:769\u201378.","journal-title":"Hypertens Res"},{"key":"1008_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharm. 2015;769:266\u201373.","journal-title":"Eur J Pharm"},{"key":"1008_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1124\/jpet.116.234765","volume":"358","author":"K Arai","year":"2016","unstructured":"Arai K, Morikawa Y, Ubukata N, Tsuruoka H, Homma T. CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats. J Pharm Exp Ther. 2016;358:548\u201357.","journal-title":"J Pharm Exp Ther"},{"key":"1008_CR12","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","volume":"42","author":"H Itoh","year":"2019","unstructured":"Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res. 2019;42:1572\u201381.","journal-title":"Hypertens Res"},{"key":"1008_CR13","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2215\/CJN.14751218","volume":"14","author":"S Ito","year":"2019","unstructured":"Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clin J Am Soc Nephrol. 2019;14:1161\u201372.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1008_CR14","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s41440-020-0495-0","volume":"43","author":"K Arai","year":"2020","unstructured":"Arai K, Morikawa Y, Ubukata N, Sugimoto K. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker. Hypertens Res. 2020;43:1204\u201313.","journal-title":"Hypertens Res"},{"key":"1008_CR15","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol. 2020;15:1715\u201327.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1008_CR16","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s10157-021-02075-y","volume":"25","author":"S Ito","year":"2021","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study. Clin Exp Nephrol. 2021;25:1070\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"1008_CR17","doi-asserted-by":"crossref","unstructured":"VanderWeele TJ. Explanation in Causal Inference: Methods for Mediation and Interaction. Oxford University Press: New York, USA, 2015.","DOI":"10.1093\/ije\/dyw277"},{"key":"1008_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/jama.2018.21973","volume":"321","author":"H Lee","year":"2019","unstructured":"Lee H, Herbert RD, McAuley JH. Mediation analysis. JAMA. 2019;321:697\u20138.","journal-title":"JAMA"},{"key":"1008_CR19","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/EDE.0b013e31826d0f6f","volume":"23","author":"S Vansteelandt","year":"2012","unstructured":"Vansteelandt S. Understanding counterfactual-based mediation analysis approaches and their differences. Epidemiology. 2012;23:889\u201391.","journal-title":"Epidemiology"},{"key":"1008_CR20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1515\/em-2012-0010","volume":"2","author":"TJ VanderWeele","year":"2014","unstructured":"VanderWeele TJ, Vansteelandt S. Mediation analysis with multiple mediators. Epidemiol Methods. 2014;2:95\u2013115.","journal-title":"Epidemiol Methods"},{"key":"1008_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/EDE.0000000000000596","volume":"28","author":"S Vansteelandt","year":"2017","unstructured":"Vansteelandt S, Daniel RM. Interventional effects for mediation analysis with multiple mediators. Epidemiology. 2017;28:258\u201365.","journal-title":"Epidemiology"},{"key":"1008_CR22","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1001\/jama.2021.14075","volume":"326","author":"H Lee","year":"2021","unstructured":"Lee H, Cashin AG, Lamb SE, Hopewell S, Vansteelandt S, VanderWeele TJ, et al. A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies: the AGReMA Statement. JAMA. 2021;326:1045\u201356.","journal-title":"JAMA"},{"key":"1008_CR23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"1008_CR24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.107.091058","volume":"50","author":"M Nagase","year":"2007","unstructured":"Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension. 2007;50:877\u201383.","journal-title":"Hypertension"},{"key":"1008_CR25","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.2337\/dc14-1296","volume":"37","author":"KR Tuttle","year":"2014","unstructured":"Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37:2864\u201383.","journal-title":"Diabetes Care"},{"key":"1008_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7:128\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1008_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","volume":"7","author":"J Coresh","year":"2019","unstructured":"Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7:115\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1008_CR28","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/rssb.12194","volume":"79","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Tchetgen Tchetgen EJ. Mediation analysis with time varying exposures and mediators. J R Stat Soc Ser B Stat Methodol. 2017;79:917\u201338.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"1008_CR29","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1177\/09622802211025988","volume":"30","author":"S Yamamuro","year":"2021","unstructured":"Yamamuro S, Shinozaki T, Iimuro S, Matsuyama Y. Mediational g-formula for time-varying treatment and repeated-measured multiple mediators: application to atorvastatin\u2019s effect on cardiovascular disease via cholesterol lowering and anti-inflammatory actions in elderly type 2 diabetics. Stat Methods Med Res. 2021;30:1782\u201399.","journal-title":"Stat Methods Med Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01008-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01008-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01008-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:08:34Z","timestamp":1675642114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01008-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1008"],"URL":"https:\/\/doi.org\/10.1038\/s41440-022-01008-w","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"assertion":[{"value":"10 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YO and TS are employees of Daiichi Sankyo Co., Ltd. SI, NK, KS, MN and TW have received personal fees from Daiichi Sankyo Co., Ltd., and MT has received consultant fees from Daiichi Sankyo Co., Ltd. NK, KS and MN have received grants\/research funding from Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}